{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% confidence interval has not reached yet for the median OS measure","groupId":"OG000","lowerLimit":"0.5","upperLimit":"NA","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Overall survival (OS) is defined to be the time from registration to death from any cause, with follow-up censored at the date of last contact. Kaplan-Meier method was used to estimate the distribution of OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.\n\nTransplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.\n\nAcute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD.\n\nCyclosporine: Immunosuppressant\n\nMethotrexate: Antimetabolite","id":"OG000","title":"Arm I"}],"paramType":"MEDIAN","populationDescription":"eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"years"}